[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"adenocarcinoma-of-the-rectum\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:adenocarcinoma-of-the-rectum":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,42,70,100,124,152,182],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100445456","five-or-ten-year-colonoscopy-for-1-2-non-advanced-adenomatous-polyps-100445456",false,"NCT05080673","Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps","FORTE","Inclusion Criteria:\n\n* The participant must have signed and dated an IRB-approved consent form that conforms to federal and institutional guidelines.\n* Participants greater than or equal to 45 and less than 70 years of age at the time of colonoscopy.\n* Participants with a first-time diagnosis of 1-2 non-advanced tubular adenomas (less than 10 mm without tubulovillous or villous changes or high grade or severe dysplasia) from the qualifying colonoscopy within 4 years prior to randomization.\n* Sessile serrated polyps\u002Fadenomas, as long as they do not meet the criteria for advanced adenomas, will be considered as non-advanced adenomas.\n* Qualifying colonoscopy must be a complete colonoscopy with visualization of the cecum and with adequate cleansing within 4 years prior to randomization.\n* Complete excision of all observed polyps in qualifying colonoscopy\n* Participants must be able to read or understand English or Spanish.\n\nExclusion Criteria:\n\n* • Prior history of colorectal cancer or colorectal adenomas including sessile serrated polyps\u002Fadenomas excluding those found on the qualifying colonoscopy.\n\n  * Prior history of a hyperplastic polyp measuring greater than or equal to 1 cm in size.\n  * Traditional serrated adenomas found on the qualifying colonoscopy.\n  * Hyperplastic polyp measuring greater than or equal to 1 cm in size found on the qualifying colonoscopy.\n  * Previous malignancies unless the patient has been disease-free for 5 or more years prior to randomization and is deemed by the physician to be at low risk for recurrence. Patients with the following cancers are eligible if diagnosed and treated within the past 5 years: all in situ cancers and basal cell and squamous cell carcinoma of the skin.\n  * Colonoscopy performed after the qualifying colonoscopy but prior to randomization.\n  * Incomplete qualifying colonoscopy (e.g., cecum not visualized).\n  * Incomplete endoscopic excision of adenomatous polyps based on colonoscopist impression at qualifying colonoscopy. (Excision of all hyperplastic rectosigmoid polyps is not required.)\n  * Sub-total colectomy or total proctocolectomy. (Segmental resections are allowed.)\n  * Family history of CRC diagnosed at less than or equal to 60 years of age in a first degree relative (mother, father, child, sibling) or in two first degree relatives with CRC at any age.\n  * Participants with a clinical diagnosis of a significant heritable risk for colorectal cancer (Familial Adenomatous Polyposis, Hereditary Nonpolyposis Colorectal Cancer \\[Lynch Syndrome\\]).\n  * Participants tested positive for a Familial Adenomatous Polyposis, Hereditary Nonpolyposis Colorectal Cancer \\[Lynch Syndrome\\] genetic mutation that increases risk of colorectal cancer.\n  * Inflammatory bowel disease (e.g., Crohn's Disease, ulcerative colitis).\n  * Life expectancy less than 10 years due to comorbid conditions in the opinion of the investigator.\n  * Other comorbid conditions that would prevent the participant from having colonoscopies or would prevent required follow-up.","ALL","45 Years","70 Years",{"count":20,"type":21},9500,"ESTIMATED","INTERVENTIONAL",[24],"NA","This trial examines colorectal cancer incidence in participants with 1 to 2 non-advanced adenomas randomized to surveillance colonoscopy at 10 years compared to participants randomized to surveillance colonoscopy at 5 and 10 years.",[27,28],"Adenocarcinoma of the Colon","Adenocarcinoma of the Rectum","RECRUITING","2026-07-01",{"date":32,"type":33},"2026-07-02","ACTUAL",{"date":35,"type":33},"2022-02-09",{"date":37,"type":21},"2065-11-01",{"name":39,"class":40},"NRG Oncology","OTHER",485,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},"100565075","a-study-of-response-to-standard-treatment-before-surgery-in-people-with-rectal-cancer-100565075","NCT06637462","A Study of Response to Standard Treatment Before Surgery in People With Rectal Cancer","DISCRN in Rectal Cancer: DISseCting Response to Neoadjuvant Therapy in Rectal Cancer","Inclusion Criteria:\n\n* 18 years of age or older on day of signing informed consent.\n* Have a histologically confirmed diagnosis of invasive adenocarcinoma of the rectum with no known mismatch repair deficiency or Her2 amplification.\n* Eligible for and plan to initiate standard-of-care therapy with any of the following regimens:\n\n  * Induction fluoropyrimidine (capecitabine \\[preferred\\] or 5-FU) based chemoradiation\n  * With plan for consolidative CAPEOX, FOLFOX, or FOLIRINOX\n* Woman with childbearing potential who are negative for pregnancy test (urine or blood) and who agree to use an effective contraceptive method. A woman of childbearing potential is defined as one who is biologically capable of becoming pregnant. Reliable contraception should be used from the time of screening and must be continued throughout the duration of treatment as per standard of care.\n\nExclusion Criteria:\n\n* Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen.\n* Patients with prior external beam radiation therapy to the pelvis or brachytherapy seed implantation of the prostate.\n* Patients who are pregnant or breastfeeding.\n* Men or women not using effective contraception.\n* Patients with a contraindication to MR imaging.\n* Patients on blood thinners prohibiting endoluminal tumor biopsies.","18 Years",{"count":51,"type":21},60,[24],"The purpose of the study is to learn more about how the body responds to standard treatment (chemoradiation and chemotherapy). The study will use the results of testing down on participants' blook, tissue, and scans to learn more about how people with rectal cancer respond to chemoradiation and chemotherapy treatment and if it is useful for predicting whether a person's cancer get better, gets worse, or stats the same after treatment.",[55,28],"Rectal Cancer",[57,58,59,60],"rectal cancer","adenocarcinoma of the rectum","Memorial Sloan Kettering Cancer Center","24-238","2026-06-01",{"date":63,"type":33},"2026-06-02",{"date":65,"type":33},"2024-10-09",{"date":67,"type":21},"2027-10-09",{"name":59,"class":40},6,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":22,"phases":79,"briefSummary":81,"conditions":82,"keywords":86,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":5},"100490930","phase-2-a-study-of-tucatinib-and-trastuzumab-in-people-with-rectal-cancer-100490930","NCT05672524","A Study of Tucatinib and Trastuzumab in People With Rectal Cancer","A Phase II Study of Induction Tucatinib and Trastuzumab With Total Neoadjuvant Therapy for Locally Advanced HER2-amplified Rectal Adenocarcinoma","Inclusion Criteria:\n\n* Willing and able to provide written informed consent for the trial.\n* Be ≥18 years of age on the date of signing informed consent.\n* ECOG performance status of 0 or 1.\n* Histologically confirmed rectal adenocarcinoma.\n* Adenocarcinoma with distal margin of 15 cm or less from the anal verge on endoscopy, staged with endorectal ultrasound (ERUS) or magnetic resonance imaging (MRI) as cT3\u002FcT4 N0 or cT(any) cN1\u002F2,\n* No evidence of distant metastases\n* Radiologically measurable or clinically evaluable disease per Protocol Section 13.0.\n* Have confirmed HER2-positive rectal adenocarcinoma, as defined by having tumor tissue tested at a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory, meeting at least one of the following criteria:\n\n  1. HER2+ overexpression (3+ immunohistochemistry \\[IHC\\]) by an FDA-approved HER2 IHC test following the package insert's interpretational manual for gastric cancer\n  2. HER2 2+ IHC is eligible if the tumor is amplified by an FDA-approved HER2 in situ hybridization assay (FISH or chromogenic in situ hybridization \\[CISH\\]) following the package insert's interpretational manual for gastric cancer\n  3. HER2 (ERBB2) amplification by CLIA-certified Next Generation Sequencing (NGS) sequencing assay.\n* Tumor specimen that demonstrates intact mismatch repair enzymes by immunohistochemistry or microsatellite stability as demonstrated by NGS or PCR.\n* Tumor specimen that indicates RAS wild-type based on expanded RAS testing including KRAS exon 2 (codons 12 and 13), exon 3 (codons 59 and 61), and exon 4 (codons 117 and 146)\n* Left ventricular ejection fraction \\>=50 assessed by echocardiography\n* Negative pregnancy test done within 14 days prior to beginning treatment, for women of childbearing potential only. Subjects of childbearing potential must be willing to use an adequate method of contraception. Appropriate methods of birth control include abstinence, oral contraceptives, implantable hormonal contraceptives, or double barrier method (diaphragm plus condom). Contraception is required for the course of the study starting with the first dose of study medication through 150 days after the last dose of study medication. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.\n\nNonchildbearing potential is defined as follows (by other than medical reasons):\n\n* ≥45 years of age and has not had menses for \\>1 year\n* Patients who have been amenorrhoeic for \\\u003C2 years without history of a hysterectomy and oophorectomy must have a follicle stimulating hormone value in the postmenopausal range upon screening evaluation\n* Post-hysterectomy, post-bilateral oophorectomy, or post-tubal ligation. Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound. Tubal ligation must be confirmed with medical records of the actual procedure, otherwise the patient must be willing to use 2 adequate barrier methods throughout the study.\n* Demonstrate adequate organ function as defined in the Table 6-1 below within 14 days of Cycle 1 Day 1, all screening labs should be performed within 14 days of treatment initiation.\n\n  * Absolute neutrophil count (ANC): ≥1,500 \u002Fmm3\n  * Platelets: ≥100,000 \u002F mcL\n  * Hemoglobin: \\>9 g\u002FdL or ≥5.6 mmol\u002FL\n  * Serum creatinine OR Measured or calculated creatinine clearance (Creatinine clearance should be calculated per institutional standard.) (GFR can also be used in place of creatinine or CrCl): ≤1.5 × upper limit of normal (ULN) OR ≥60 mL\u002Fmin for subject with creatinine levels \\> 1.5 × institutional ULN\n  * Serum total bilirubin: Total bilirubin ≤ 1.5 × upper limit of normal (ULN), except for subjects with known Gilbert's disease who may enroll if the conjugated bilirubin is ≥1.5 x ULN\n  * AST (SGOT) and ALT (SGPT): ≤ 2.5 × ULN\n  * International Normalized Ratio (INR) or Prothrombin Time (PT) Activated Partial Thromboplastin Time (aPTT): For patients not taking warfarin: INR \\\u003C1.5 or PT \\\u003C1.5 x ULN; and either PTT or aPTT \\\u003C1.5 x ULN. Patients on warfarin may be included on a stable dose with a therapeutic INR \\\u003C3.5\n\nExclusion Criteria:\n\n* Recurrent rectal cancer.\n* Prior pelvic radiation therapy, chemotherapy, or surgery for rectal cancer.\n* Tumor is causing symptomatic bowel obstruction (patients who have a temporary diverting ostomy are eligible).\n* Other invasive malignancy ≤ 5 years prior to registration. Exceptions are non-melanoma skin cancer that has undergone potentially curative therapy and in situ cervical carcinoma.\n* Active infection requiring systemic therapy.\n* Other Anticancer or Experimental Therapy. No other experimental therapies (including chemotherapy, radiation, hormonal treatment, antibody therapy, immunotherapy, gene therapy, vaccine therapy, angiogenesis inhibitors, matrix metalloprotease inhibitors, thalidomide, anti-VEGF\u002FFlk-1 monoclonal antibody or other experimental drugs) of any kind are permitted while the patient is receiving study treatment.\n* Known history of Human Immunodeficiency Virus (HIV) (HIV 1\u002F2 antibodies)\n* Known active Hepatitis B (e.g., HbsAg reactive) or Hepatitis C (e.g., HCV RNA \\[qualitative\\] is detected).\n* Any known chronic (non-transient) liver disease in the patient's past medical history such as (but not limited to) cirrhosis, NASH (non-alcoholic steatohepatitis) or NAFLD.\n* Women who are pregnant or breastfeeding, or men expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening visit through 150 days after the last dose of study medication.\n* Concurrent medical or psychiatric condition or disease which, in the investigator's judgement, would make them inappropriate candidates for entry into the study. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 90 days) myocardial infarction, chronic obstructive pulmonary disease, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, or any psychiatric disorder that prohibits obtaining informed consent.\n* Received a live vaccine within 30 days of planned start of study medication.\n* Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to enrollment.\n* Inability to swallow pills or any significant gastrointestinal disease which would preclude the adequate oral absorption of medications\n* Use of a strong cytochrome P450 (CYP)2C8 inhibitor that is not adequately cleared (five half-lives of elapsed time) before study initiation. In addition, use of a strong CYP3A4 or CYP2C8 inducer that is taken within 5 days prior to the first dose of study will also be an exclusion criteria.",{"count":78,"type":21},37,[80],"PHASE2","The study researchers believe that a combination of the drugs trastuzumab and tucatinib, given with standard chemotherapy (capecitabine and oxaliplatin\u002FFOLFOX), may help participants with rectal cancer.",[28,83,84,85,55],"Locally Advanced Rectal Adenocarcinoma","Rectal Adenocarcinoma","HER2 Positive Rectal Adenocarcinoma",[87,88,28,83,84,55,89,90,59,91],"HER2 positive rectal adenocarcinoma","Adenocarcinoma","Tucatinib","Trastuzumab","22-185","2026-05-11",{"date":94,"type":33},"2026-05-12",{"date":96,"type":33},"2022-12-30",{"date":98,"type":21},"2030-07-31",{"name":59,"class":40},{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":108,"phases":4,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":123},"100410442","the-utility-and-feasibility-of-mt-sdna-as-a-surveillance-procedure-in-colorectal-cancer-survivors-100410442","NCT04624555","The Utility and Feasibility of Mt-sDNA as a Surveillance Procedure in Colorectal Cancer Survivors","Inclusion Criteria:\n\n* Diagnosis of stage I, II or III adenocarcinoma of the colon or rectum\n* Receipt of preoperative colonoscopy\n* Receipt of bowel resection; use of adjuvant chemotherapy or radiation therapy as clinically indicated\n\nExclusion Criteria:\n\n* Stage IV colorectal cancer\n* Surgical treatment with subtotal colectomy or total proctocolectomy\n* Diagnosis of inflammatory bowel disease (ulcerative colitis or Crohn's disease)\n* Diagnosis of polyposis syndrome including Lynch syndrome or familial polyposis\n* Presence of advanced adenomas (1 cm or larger, villous features and\u002For high grade dysplasia) that were not removed at the preoperative colonoscopy or contained in the resection specimen.\n* Inability to provide informed consent\n* Inability to understand spoken and written English\n* Medical comorbidities that would be contraindications to sedation or that would preclude any benefit of routine surveillance post-resection. These would be at the discretion of the participant's providers.",{"count":107,"type":21},50,"OBSERVATIONAL","The purpose of this research study is to determine whether testing of stool for a panel of markers will enable us to detect polyps and cancer compared to standard testing.",[27,28,111,112,113],"Stage I Colorectal Cancer","Stage II Colorectal Cancer","Stage III Colorectal Cancer","2026-04-06",{"date":116,"type":33},"2026-04-09",{"date":118,"type":33},"2022-10-31",{"date":120,"type":21},"2026-09-01",{"name":122,"class":40},"Case Comprehensive Cancer Center",1,{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":131,"targetDuration":4,"studyType":108,"phases":4,"briefSummary":133,"conditions":134,"keywords":139,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":123},"100413844","biopsy-after-radioembolization-to-identify-changes-in-tumor-cells-from-the-radiation-100413844","NCT04668872","Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation","Correlation of Histopathological Findings With Radiation Exposure Levels After Y90 Transarterial Radioembolization (TARE) of Hepatic Metastases: A Feasibility Study","Inclusion Criteria:\n\n* age ≥ 18 years\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n* histologically confirmed primary adenocarcinoma of the colon or rectum\n* CLM considered unresectable or not amenable to percutaneous ablation\n* existent tissue samples from a standard of care biopsy of the target tumor within 42 days prior to treatment OR clinical indication for biopsy at the time of the treatment under the institutional guidelines for progression of disease.\n* adequate blood cell counts (WBC \\> 1.5 x 109\u002FL, platelet count \\> 50 x 109\u002FL)\n* adequate renal function (creatinine \\\u003C 1.5 mg\u002FdL)\n* total bilirubin level ≤ 1.5 mg\u002FdL\n\nAdditional inclusion criteria for patients, undergoing 90Y radiation segmentectomy:\n\nA. patients not amenable to surgery or thermal ablation\n\nExclusion Criteria:\n\nStudy exclusion criteria will be similar to general TARE exclusion criteria, which are as follows:\n\n* prior hepatic radiotherapy (The lesion \u002F lobe being treated cannot have had prior treatment with radiotherapy - untreated lesions \u002F lobes in the liver may be evaluated under the protocol)\n* severe cirrhosis\n* severe portal hypertension\n* uncorrectable flow to the gastrointestinal tract and\u002For \\>30 Gy (or \\>50 Gy in multiple sessions) radiation absorbed dose to the lungs\n\nAll patients with liver-dominant disease will be considered candidates for TARE even in the face of oligometastatic (up to 5 sites) extrahepatic disease, that is stable or controlled by chemotherapy.",{"count":132,"type":21},80,"The purpose of this study is to study the way radioembolization works by collecting biopsy samples of participants' tumors after the procedure. This research may improve the way that radioembolization is performed, which could help people whose cancer has spread to the liver. The research may also provide information about how tumors respond to radioembolization.",[135,136,27,28,137,138],"Colon Cancer Liver Metastasis","Colon Cancer","Liver Metastasis Colon Cancer","Colorectal Cancer",[140,141,142,135,136,27,28,138,59,143],"colorectal liver metastases","transarterial radioembolization","Y90 TARE","20-355","2026-03-11",{"date":146,"type":33},"2026-03-12",{"date":148,"type":33},"2020-12-07",{"date":150,"type":21},"2026-12-07",{"name":59,"class":40},{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":160,"enrollmentInfo":161,"targetDuration":4,"studyType":22,"phases":163,"briefSummary":164,"conditions":165,"keywords":166,"overallStatus":172,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":123},"100612839","short-course-or-long-course-radiotherapy-as-total-neoadjuvant-therapy-in-locally-advanced-rectal-cancer-100612839","NCT07258797","Short Course or Long Course Radiotherapy as Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer","Short Course or Long Course Radiotherapy as Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer : A Prospective, Open Label, Single Institution, Randomized, Parallel Arm Comparative Study","SHOOL","Inclusion Criteria:\n\n1. Histologically confirmed adenocarcinoma of the rectum\n2. Locally advanced disease based on MRI including cT3-T4 and\u002For node positive disease (cN1 or N2)\n3. Tumor located within 15 cm from the anal verge (confirmed by endoscopy or MRI)\n4. ECOG performance status 0-2\n5. Hemoglobin ≥ 9 g\u002FdL\n6. Absolute neutrophil count ≥ 1,500\u002Fmm³\n7. Platelets ≥ 100,000\u002Fmm³\n8. Total bilirubin ≤ 1.5 × ULN\n9. Aspartate transaminase\u002FAlanine transaminase ≤ 2.5 × ULN\n10. Serum creatinine ≤ 1.5 × ULN or creatinine clearance ≥ 60 mL\u002Fmin\n11. Fit for neoadjuvant therapy and curative resection\n12. Willing and able to provide written, informed consent\n13. Baseline MRI and biopsy (even if done outside) must be reviewed and approved by the institutional radiology and pathology review board, requiring concurrence from two independent pathologists and two independent radiologists\n\nExclusion Criteria:\n\n1. Metastatic disease at presentation (distant nodes, liver, lung, peritoneum, etc.)\n2. Prior pelvic radiotherapy or systemic chemotherapy for rectal cancer\n3. Presence of synchronous malignancies or previous malignancy within 5 years except: Treated basal cell or squamous cell carcinoma of the skin, In situ cervical cancer, Active uncontrolled infection\n4. Known HIV infection with CD4 \\\u003C 200 cells\u002FμL, or active hepatitis B or C\n5. Severe comorbid conditions precluding therapy (e.g., decompensated cardiac, hepatic, or renal disease)\n6. Pregnant or breastfeeding women\n7. Inability to comply with protocol requirements or follow-up schedule\n8. Psychiatric illness or social situations that may limit compliance with study requirements","75 Years",{"count":162,"type":21},150,[24],"This study compares two standard radiotherapy approaches (short-course vs. long-course) given before surgery in patients with locally advanced rectal cancer. The goal is to see which treatment is more effective and better tolerated.",[28],[167,168,169,170,171],"SHORT COURSE RADIOTHERAPY","LONG COURSE RADIOTHERAPY","RECTAL CANCER","OUTCOMES","SURVIVAL","NOT_YET_RECRUITING","2025-11-20",{"date":175,"type":33},"2025-12-02",{"date":177,"type":21},"2025-12-01",{"date":179,"type":21},"2029-03-31",{"name":181,"class":40},"Rajiv Gandhi Cancer Institute & Research Center, India",{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":186,"acronym":187,"eligibilityCriteria":188,"healthyVolunteers":11,"sex":16,"minAge":189,"maxAge":4,"enrollmentInfo":190,"targetDuration":4,"studyType":22,"phases":192,"briefSummary":193,"conditions":194,"keywords":195,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":123},"100309071","concordance-of-imaging-and-pathology-diagnosis-of-extranodal-tumour-deposits-100309071","NCT03303547","Concordance of Imaging and Pathology Diagnosis of Extranodal Tumour Deposits","COMET","Inclusion Criteria:\n\n1. Suspected primary adenocarcinoma of the colon, sigmoid or rectum (proven by biopsy taken as part of routine clinical practice, patients to be withdrawn if not subsequently adenocarcinoma on pathology).\n2. Amenable to surgical resection.\n3. Disease spread assessed on imaging\n4. Patients having primary surgery and those undergoing neoadjuvant treatment will be included.\n5. All must have had baseline staging scans and those undergoing neoadjuvant therapy must also have had a post-treatment scan.\n6. Patients aged 16 years and over\n\nExclusion Criteria:\n\n1. Patients with recurrent tumours\n2. Synchronous tumours\n3. Under the age of 16 years\n4. Unable to give informed consent.","16 Years",{"count":191,"type":21},200,[24],"Any patient with a suspected primary adenocarcinoma of the colon, sigmoid or rectum undergoing surgery are eligible. The date of surgery must be known prior to registration. This trial aims to determine if image mapping techniques can improve the concordance between imaging and pathology detection of tumour deposits. Lymph nodes and tumour deposits will be identified on pre-operative scans and mapped by radiologists then shared with pathologists prior to processing the resected specimen. Patients will be managed at their local hospital with standard follow-up. Patients will be followed up for 5 years.",[28],[196,197,198,199,200,201],"MRI","Tissue","Imaging","Pathology","Rectal","Cancer","2024-10-16",{"date":204,"type":33},"2024-10-17",{"date":206,"type":33},"2017-10-16",{"date":208,"type":21},"2031-12",{"name":210,"class":40},"Imperial College London"]